Hi all, on the theme of statistics, I attempted some modelling this afternoon on what minimum results in survival might be needed to conclude a significant benefit for the primary outcome at either interim or final stages of the COVID-19 ARDS trial. I do not have a medical research background and this may well be over-simplistic or incorrect. I'd be interested to hear comments from others on these numbers or factors that might come into consideration.
Hi all, on the theme of statistics, I attempted some modelling...
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
0.065(5.88%) |
Mkt cap ! $1.290B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.19 | $1.09 | $6.854M | 6.009M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 10613 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 32236 | 6 |
View Market Depth
| Last trade - 12.24pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |